מדינה: ישראל
שפה: עברית
מקור: Ministry of Health
PALIVIZUMAB 100 MG
ABBVIE BIOPHARMACEUTICALS LTD, ISRAEL
J06BB16
POWDER FOR SOLUTION FOR INJECTION
I.M
ABBVIE S.R.L., ITALY
PALIVIZUMAB
Is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV). Safety and efficacy were established in infants with bronchopulmonary dysplasia (BPD) and in infants with a history of prematurity (35 weeks gestational age) and in children less then 2 years of age,with haemodynamically significant congenital heart disease.
2010-06-01